KR20240043792A - 조작된 고충실도 omni-50 뉴클레아제 변이체 - Google Patents
조작된 고충실도 omni-50 뉴클레아제 변이체 Download PDFInfo
- Publication number
- KR20240043792A KR20240043792A KR1020247007872A KR20247007872A KR20240043792A KR 20240043792 A KR20240043792 A KR 20240043792A KR 1020247007872 A KR1020247007872 A KR 1020247007872A KR 20247007872 A KR20247007872 A KR 20247007872A KR 20240043792 A KR20240043792 A KR 20240043792A
- Authority
- KR
- South Korea
- Prior art keywords
- omni
- amino acid
- nuclease
- variant
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232571P | 2021-08-12 | 2021-08-12 | |
| US63/232,571 | 2021-08-12 | ||
| US202263332214P | 2022-04-18 | 2022-04-18 | |
| US63/332,214 | 2022-04-18 | ||
| US202263333037P | 2022-04-20 | 2022-04-20 | |
| US63/333,037 | 2022-04-20 | ||
| PCT/US2022/074930 WO2023019263A1 (en) | 2021-08-12 | 2022-08-12 | Engineered high fidelity omni-50 nuclease variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240043792A true KR20240043792A (ko) | 2024-04-03 |
Family
ID=85201002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007872A Pending KR20240043792A (ko) | 2021-08-12 | 2022-08-12 | 조작된 고충실도 omni-50 뉴클레아제 변이체 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250283115A1 (https=) |
| EP (1) | EP4384609A4 (https=) |
| JP (1) | JP2024531217A (https=) |
| KR (1) | KR20240043792A (https=) |
| AU (1) | AU2022326575A1 (https=) |
| CA (1) | CA3228366A1 (https=) |
| IL (1) | IL310730A (https=) |
| WO (1) | WO2023019263A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| KR20230142740A (ko) | 2021-02-08 | 2023-10-11 | 에멘도바이오 인코포레이티드 | Omni-103 crispr 뉴클레아제 |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| US20260021141A1 (en) * | 2022-07-15 | 2026-01-22 | Emendobio Inc. | Strategies For Knock-Ins At APLP2 Safe Harbor Sites |
| WO2025117858A1 (en) * | 2023-11-28 | 2025-06-05 | Metagenomi, Inc. | Supplementation of liver enzyme expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512446B1 (en) * | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2020223514A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni-50 crispr nuclease |
| WO2020223553A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni crispr nucleases |
| US12435334B2 (en) * | 2019-11-06 | 2025-10-07 | Emendobio Inc. | Differential knockout of an allele of a heterozygous ELANE gene-II |
| WO2024168159A1 (en) * | 2023-02-08 | 2024-08-15 | Emendobio Inc. | Engineered omni-50 nuclease variants |
-
2022
- 2022-08-12 IL IL310730A patent/IL310730A/en unknown
- 2022-08-12 CA CA3228366A patent/CA3228366A1/en active Pending
- 2022-08-12 AU AU2022326575A patent/AU2022326575A1/en active Pending
- 2022-08-12 US US18/682,982 patent/US20250283115A1/en active Pending
- 2022-08-12 JP JP2024508545A patent/JP2024531217A/ja active Pending
- 2022-08-12 EP EP22856846.5A patent/EP4384609A4/en active Pending
- 2022-08-12 WO PCT/US2022/074930 patent/WO2023019263A1/en not_active Ceased
- 2022-08-12 KR KR1020247007872A patent/KR20240043792A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022326575A1 (en) | 2024-03-14 |
| JP2024531217A (ja) | 2024-08-29 |
| IL310730A (en) | 2024-04-01 |
| WO2023019263A1 (en) | 2023-02-16 |
| EP4384609A1 (en) | 2024-06-19 |
| CA3228366A1 (en) | 2023-02-16 |
| EP4384609A4 (en) | 2025-07-02 |
| US20250283115A1 (en) | 2025-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050582A (ja) | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ | |
| KR20240043792A (ko) | 조작된 고충실도 omni-50 뉴클레아제 변이체 | |
| JP2023531384A (ja) | 新規なｏｍｎｉ－５９、６１、６７、７６、７９、８０、８１及び８２クリスパーヌクレアーゼ | |
| JP2024545144A (ja) | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ－ｒｎａ複合体 | |
| JP2024516161A (ja) | 新規なｏｍｎｉ－１１７、１４０、１５０～１５８、１６０～１６５、１６７～１７７、１８０～１８８、１９１～１９８、２００、２０１、２０３、２０５～２０９、２１１～２１７、２１９、２２０、２２２、２２３、２２６、２２７、２２９、２３１～２３６、２３８～２４５、２４７、２５０、２５４、２５６、２５７、２６０及び２６２ ｃｒｉｓｐｒヌクレアーゼ | |
| JP2023549139A (ja) | 新規ｏｍｎｉ－５０ ｃｒｉｓｐｒヌクレアーゼ－ｒｎａ複合体 | |
| JP2024542883A (ja) | 改変された忠実度の高いｏｍｎｉ－７９ヌクレアーゼバリアント | |
| KR20240045285A (ko) | 신규한 omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 및 259 crispr 뉴클레아제 | |
| JP2024540558A (ja) | 新規なｏｍｎｉ ｃｒｉｓｐｒヌクレアーゼ | |
| JP2024506608A (ja) | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ | |
| JP2023546694A (ja) | 新規のｏｍｎｉ５６、５８、６５、６８、７１、７５、７８及び８４ｃｒｉｓｐｒヌクレアーゼ | |
| AU2024217244A1 (en) | Engineered omni-50 nuclease variants | |
| CN117279671A (zh) | 用于在c3安全港位点处敲入的策略 | |
| CN118176295A (zh) | 工程化高保真度omni-50核酸酶变体 | |
| HK40112369A (zh) | 工程化高保真度omni-50核酸酶变体 | |
| KR20250130659A (ko) | Omni xl 1-22 crispr 뉴클레아제 | |
| HK40115104A (zh) | 工程化高活性omni-79核酸酶变体 | |
| KR20250130360A (ko) | Omni-355 crispr 뉴클레아제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |